UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Expert opinion on pharmacotherapy, ISSN 1465-6566, 10/2018, Volume 19, Issue 15, pp. 1731 - 1738
Adherence | Glaucoma | beta-adrenergic antagonis | Prostaglandin analogues | Ocular hypertension | tolerability | Carteolol | fixed-combination carteolol-latanoprost | Latanoprost | Antihypertensive Agents - pharmacology | Latanoprost - pharmacology | Carteolol - therapeutic use | Humans | Carteolol - pharmacology | Glaucoma - drug therapy | Latanoprost - therapeutic use | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Ocular Hypertension - drug therapy | Drug Therapy, Combination - methods | Latanoprost - pharmacokinetics | Carteolol - pharmacokinetics | Female | Index Medicus
Journal Article
Expert review of ophthalmology, ISSN 1746-9899, 01/2019, Volume 14, Issue 1, pp. 61 - 72
Journal Article
Journal of ophthalmic & vision research, ISSN 2008-2010, 07/2020, Volume 15, Issue 3, pp. 408 - 411
Journal Article
Journal of glaucoma, ISSN 1057-0829, 10/2018, Volume 27, Issue 10, pp. 856 - 863
Journal Article
Expert opinion on pharmacotherapy, ISSN 1465-6566, 01/2020, Volume 21, Issue 1, pp. 39 - 45
Adherence | fixed-combination netarsudil (AR-1324)-latanoprost | latanoprost | ocular hypertension | prostaglandin analogues | glaucoma | tolerability | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Latanoprost - administration & dosage | Intraocular Pressure - drug effects | Humans | beta-Alanine - administration & dosage | Glaucoma - drug therapy | Male | Antihypertensive Agents - therapeutic use | Benzoates - administration & dosage | Ocular Hypertension - drug therapy | Ophthalmic Solutions | Female | beta-Alanine - analogs & derivatives | Drug Combinations | Index Medicus
Journal Article
Investigative ophthalmology & visual science, ISSN 0146-0404, 07/2018, Volume 59, Issue 8, pp. 3375 - 3384
Inflammation | Ocular surface | Dry eye | Latanoprost | Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Inflammation - chemically induced | Inflammation - pathology | Humans | Antihypertensive Agents - administration & dosage | Tears - metabolism | NF-kappa B - metabolism | Epithelium, Corneal - physiology | Occludin - metabolism | Occludin - genetics | Dry Eye Syndromes - pathology | Antihypertensive Agents - toxicity | Inflammation - metabolism | Matrix Metalloproteinase 9 - metabolism | Cornea - drug effects | Matrix Metalloproteinase 9 - genetics | Female | Cornea - pathology | p38 Mitogen-Activated Protein Kinases - metabolism | Zonula Occludens-1 Protein - metabolism | Real-Time Polymerase Chain Reaction | Fluorescent Antibody Technique, Indirect | In Situ Nick-End Labeling | Zonula Occludens-1 Protein - genetics | Latanoprost - administration & dosage | Enzyme-Linked Immunosorbent Assay | Mice, Inbred C57BL | p38 Mitogen-Activated Protein Kinases - genetics | Matrix Metalloproteinase 3 - metabolism | Conjunctivitis - chemically induced | Latanoprost - toxicity | Blotting, Western | Conjunctivitis - pathology | Cornea - metabolism | Preservatives, Pharmaceutical | Animals | NF-kappa B - genetics | Dry Eye Syndromes - metabolism | Conjunctivitis - metabolism | Dry Eye Syndromes - chemically induced | Mice | Matrix Metalloproteinase 3 - genetics | Index Medicus
Journal Article
Medicina (Kaunas, Lithuania), ISSN 1010-660X, 07/2019, Volume 55, Issue 7, p. 366
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Benzalkonium Compounds - therapeutic use | Latanoprost - pharmacology | Prostaglandins F - therapeutic use | Dinoprost - pharmacokinetics | Cross-Sectional Studies | Tears - chemistry | Humans | Oxidative Stress - physiology | Benzalkonium Compounds - pharmacokinetics | Glaucoma - drug therapy | Latanoprost - therapeutic use | Latanoprost - pharmacokinetics | Prostaglandins F - pharmacology | Poland | Prostaglandins F - pharmacokinetics | Benzalkonium Compounds - pharmacology | Dinoprost - therapeutic use | Oxidative Stress - drug effects | Administration, Topical | Dinoprost - pharmacology | Tears - drug effects | Index Medicus | latanoprost | tears | bimatoprost | glaucoma | ocular surface | tafluprost | benzalkonium chloride
Journal Article
Advances in therapy, ISSN 0741-238X, 01/2020, Volume 37, Issue 3, pp. 1114 - 1123
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Hypertension | Glaucoma | Endothelium | Health technology assessment | Original Research | Open-angle glaucoma | Ocular hypertension | Intraocular pressure | Latanoprost | Netarsudil | latanoprost fixed combination
Journal Article
Advances in therapy, ISSN 0741-238X, 04/2020, Volume 37, Issue 4, pp. 1620 - 1631
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Benzoates - adverse effects | beta-Alanine - adverse effects | Benzoates - therapeutic use | Intraocular Pressure - drug effects | Latanoprost - adverse effects | Ophthalmic Solutions - therapeutic use | United States | Humans | Middle Aged | Ophthalmic Solutions - adverse effects | beta-Alanine - therapeutic use | Latanoprost - therapeutic use | Male | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Glaucoma, Open-Angle - drug therapy | Ocular Hypertension - drug therapy | Tonometry, Ocular | Female | Aged | beta-Alanine - analogs & derivatives | United States Food and Drug Administration | Health technology assessment | Glaucoma | Rho kinase inhibitor | Original Research | Fixed-dose combination | Ocular hypertension | Clinical trial | Prostaglandin analogue | Intraocular pressure | Latanoprost | Netarsudil
Journal Article
American journal of ophthalmology, ISSN 0002-9394, 11/2019, Volume 207, pp. 248 - 257
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Administration, Ophthalmic | Benzoates - adverse effects | Benzoates - therapeutic use | Intraocular Pressure - drug effects | Latanoprost - adverse effects | Ocular Hypertension - physiopathology | Humans | Middle Aged | Ocular Hypertension - diagnosis | Latanoprost - therapeutic use | Male | rho-Associated Kinases - antagonists & inhibitors | Ocular Hypertension - drug therapy | Ophthalmic Solutions | Tonometry, Ocular | Female | beta-Alanine - analogs & derivatives | beta-Alanine - adverse effects | Double-Blind Method | Glaucoma, Open-Angle - diagnosis | Glaucoma, Open-Angle - physiopathology | beta-Alanine - therapeutic use | Intraocular Pressure - physiology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Glaucoma, Open-Angle - drug therapy | Aged | Drug Combinations | Hypertension | Glaucoma | Clinical trials | Drug therapy, Combination | Analysis | Diabetic retinopathy | Population | Patient compliance | Index Medicus | Abridged Index Medicus
Journal Article
Experimental eye research, ISSN 0014-4835, 12/2010, Volume 91, Issue 6, pp. 853 - 859
Journal Article
Ocular immunology and inflammation, ISSN 0927-3948, 02/2019, Volume 27, Issue 2, pp. 181 - 188
Prostaglandin analogs | Macular edema | Intraocular inflammation | Iritis | Latanoprost | Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Macular Edema - etiology | Inflammation - drug therapy | Uveitis - drug therapy | Humans | Macular Edema - drug therapy | Latanoprost - therapeutic use | Antihypertensive Agents - therapeutic use | Uveitis - complications | Index Medicus
Journal Article
Cutaneous and ocular toxicology, ISSN 1556-9527, 10/2019, Volume 38, Issue 4, pp. 370 - 374
latanoprost | Choroidal thickness | prostaglandin analogs | EDI-OCT | Toxicology | Ophthalmology | Life Sciences & Biomedicine | Science & Technology | Choroid - diagnostic imaging | Latanoprost - administration & dosage | Latanoprost - adverse effects | Ocular Hypertension - pathology | Tomography, Optical Coherence | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Glaucoma, Open-Angle - pathology | Male | Antihypertensive Agents - adverse effects | Glaucoma, Open-Angle - drug therapy | Ocular Hypertension - drug therapy | Ophthalmic Solutions | Adult | Female | Aged | Administration, Topical | Choroid - pathology | Choroid - drug effects
Journal Article
Eye & contact lens, ISSN 1542-2321, 11/2018, Volume 44 Suppl 2, pp. S93 - S98
Life Sciences & Biomedicine | Ophthalmology | Science & Technology | Antihypertensive Agents - pharmacology | Latanoprost - pharmacology | Prospective Studies | Latanoprost - adverse effects | Humans | Middle Aged | Tears - metabolism | Latanoprost - therapeutic use | Male | Travoprost - pharmacology | Preservatives, Pharmaceutical - pharmacology | Conjunctiva - pathology | Cornea - drug effects | Aged, 80 and over | Adult | Female | Preservatives, Pharmaceutical - therapeutic use | Benzalkonium Compounds - pharmacology | Cornea - pathology | Travoprost - adverse effects | Benzalkonium Compounds - therapeutic use | Preservatives, Pharmaceutical - adverse effects | Intraocular Pressure | Benzalkonium Compounds - adverse effects | Glaucoma - drug therapy | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Conjunctiva - drug effects | Aged | Glaucoma - pathology | Travoprost - therapeutic use | Therapeutics, Ophthalmological | Dosage and administration | Health aspects | Patient outcomes | Methods | Travoprost | Index Medicus
Journal Article